BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Citrome L. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract 2015;69:1211-20. [DOI: 10.1111/ijcp.12752] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Stahl SM. Mechanism of action of cariprazine. CNS Spectr 2016;21:123-7. [PMID: 26956157 DOI: 10.1017/S1092852916000043] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
2 Ceskova E, Silhan P. Novel treatment options in depression and psychosis. Neuropsychiatr Dis Treat 2018;14:741-7. [PMID: 29559781 DOI: 10.2147/NDT.S157475] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 6.8] [Reference Citation Analysis]
3 Mallet J, Gorwood P, Le Strat Y, Dubertret C. Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review. Int J Neuropsychopharmacol 2019;22:651-64. [PMID: 31406978 DOI: 10.1093/ijnp/pyz043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tuplin EW, Holahan MR. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Curr Neuropharmacol 2017;15:1192-207. [PMID: 28412910 DOI: 10.2174/1570159X15666170413115754] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
5 Citrome L. Binge Eating Disorder: A Psychiatrist's Commentary on Clinical Considerations. Clin Ther 2021;43:7-16. [PMID: 33308878 DOI: 10.1016/j.clinthera.2020.10.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Frampton JE. Brexpiprazole: A Review in Schizophrenia. Drugs 2019;79:189-200. [PMID: 30671869 DOI: 10.1007/s40265-019-1052-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
7 Fornaro M, Fusco A, Anastasia A, Cattaneo CI, De Berardis D. Brexpiprazole for treatment-resistant major depressive disorder. Expert Opinion on Pharmacotherapy 2019;20:1925-33. [DOI: 10.1080/14656566.2019.1654457] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
8 Grunze H, Csehi R, Born C, Barabássy Á. Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System. Front Psychiatry 2021;12:803208. [PMID: 34970175 DOI: 10.3389/fpsyt.2021.803208] [Reference Citation Analysis]
9 Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 2017;7:29-41. [PMID: 28101322 DOI: 10.1177/2045125316672136] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
10 Stahl SM. Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr 2016;21:1-6. [DOI: 10.1017/s1092852915000954] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
11 Azorin JM, Simon N. Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder. Drugs 2019;79:1657-77. [PMID: 31468317 DOI: 10.1007/s40265-019-01189-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Bába LI, Kolcsár M, Kun IZ, Ulakcsai Z, Bagaméry F, Szökő É, Tábi T, Gáll Z. Effects of Cariprazine, Aripiprazole, and Olanzapine on Mouse Fibroblast Culture: Changes in Adiponectin Contents in Supernatants, Triglyceride Accumulation, and Peroxisome Proliferator-Activated Receptor-γ Expression. Medicina (Kaunas) 2019;55:E160. [PMID: 31108997 DOI: 10.3390/medicina55050160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Li P, Snyder GL, Vanover KE. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Curr Top Med Chem 2016;16:3385-403. [PMID: 27291902 DOI: 10.2174/1568026616666160608084834] [Cited by in Crossref: 106] [Cited by in F6Publishing: 79] [Article Influence: 21.2] [Reference Citation Analysis]
14 Möller D, Banerjee A, Uzuneser TC, Skultety M, Huth T, Plouffe B, Hübner H, Alzheimer C, Friedland K, Müller CP, Bouvier M, Gmeiner P. Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5- a ]pyridine Substructure. J Med Chem 2017;60:2908-29. [DOI: 10.1021/acs.jmedchem.6b01857] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
15 Di Giovanni G, Svob Strac D, Sole M, Unzeta M, Tipton KF, Mück-Šeler D, Bolea I, Della Corte L, Nikolac Perkovic M, Pivac N, Smolders IJ, Stasiak A, Fogel WA, De Deurwaerdère P. Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. Front Neurosci 2016;10:541. [PMID: 27932945 DOI: 10.3389/fnins.2016.00541] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
16 Hope J, Castle D, Keks NA. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australas Psychiatry 2018;26:92-4. [PMID: 29017334 DOI: 10.1177/1039856217732473] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Herman A, El Mansari M, Adham N, Kiss B, Farkas B, Blier P. Involvement of 5-HT1A and 5-HT2A Receptors but Not α 2-Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo. Mol Pharmacol 2018;94:1363-70. [PMID: 30322874 DOI: 10.1124/mol.118.113290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Barman R, Majumder P, Doifode T, Kablinger A. Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise? . World J Psychiatr 2021; 11(12): 1228-1238 [DOI: 10.5498/wjp.v11.i12.1228] [Reference Citation Analysis]
19 Stefanowicz J, Słowiński T, Wróbel MZ, Herold F, Gomółka AE, Wesołowska A, Jastrzębska-więsek M, Partyka A, Andres-mach M, Czuczwar SJ, Łuszczki JJ, Zagaja M, Siwek A, Nowak G, Żołnierek M, Bączek T, Ulenberg S, Belka M, Turło J. Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile. Bioorganic & Medicinal Chemistry 2016;24:3994-4007. [DOI: 10.1016/j.bmc.2016.06.038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
20 Do A, Keramatian K, Schaffer A, Yatham L. Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials. Front Psychiatry 2021;12:769897. [PMID: 34970166 DOI: 10.3389/fpsyt.2021.769897] [Reference Citation Analysis]
21 Citrome L. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr Dis Treat 2018;14:2563-77. [PMID: 30323605 DOI: 10.2147/NDT.S159704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Suzuki S, Yamamoto M, Togashi K, Sanomachi T, Sugai A, Seino S, Yoshioka T, Kitanaka C, Okada M. In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile. Oncotarget 2019;10:3547-58. [PMID: 31191825 DOI: 10.18632/oncotarget.26949] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Wróbel MZ, Chodkowski A, Herold F, Marciniak M, Dawidowski M, Siwek A, Starowicz G, Stachowicz K, Szewczyk B, Nowak G, Belka M, Bączek T, Satała G, Bojarski AJ, Turło J. Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect. European Journal of Medicinal Chemistry 2019;183:111736. [DOI: 10.1016/j.ejmech.2019.111736] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Jacobson M, Childers W, Abou‐gharbia M. Dopamine D 2 Partial Agonists – Discovery, Evolution, and Therapeutic Potential. In: Fischer J, Klein C, Childers WE, editors. Successful Drug Discovery. Wiley; 2019. pp. 83-130. [DOI: 10.1002/9783527814695.ch4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Ebrahimzadeh M, El Mansari M, Blier P. Synergistic effect of aripiprazole and escitalopram in increasing serotonin but not norepinephrine neurotransmission in the rat hippocampus. Neuropharmacology 2019;146:12-8. [DOI: 10.1016/j.neuropharm.2018.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Yoshioka T, Kitanaka C, Okada M. Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. Cancers (Basel) 2019;11:E947. [PMID: 31284441 DOI: 10.3390/cancers11070947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
27 Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. European Neuropsychopharmacology 2019;29:971-85. [DOI: 10.1016/j.euroneuro.2019.06.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
28 Wróbel MZ, Chodkowski A, Marciniak M, Dawidowski M, Maksymiuk A, Siwek A, Nowak G, Turło J. Synthesis of new 4-butyl-arylpiperazine-3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives and evaluation for their 5-HT1A and D2 receptor affinity and serotonin transporter inhibition. Bioorganic Chemistry 2020;97:103662. [DOI: 10.1016/j.bioorg.2020.103662] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
29 Romeo B, Blecha L, Locatelli K, Benyamina A, Martelli C. Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety. J Psychopharmacol 2018;32:385-96. [DOI: 10.1177/0269881118760661] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
30 Stummer L, Markovic M, Maroney M. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease. Neurodegener Dis Manag 2020;10:205-17. [PMID: 32618483 DOI: 10.2217/nmt-2020-0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Yoon S, Jeon SW, Ko Y, Patkar AA, Masand PS, Pae C, Han C. Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol 2017;37:46-53. [DOI: 10.1097/jcp.0000000000000622] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.6] [Reference Citation Analysis]
32 Wu B, Wu L, He Y, Yin Z, Deng L. Engineered PLGA microspheres for extended release of brexpiprazole: in vitro and in vivo studies. Drug Dev Ind Pharm 2021;47:1001-10. [PMID: 34032181 DOI: 10.1080/03639045.2021.1934859] [Reference Citation Analysis]
33 Ivanov SV, Voronova EI. [The newer antipsychotic cariprazine (reagila): perspectives for use in different stages of schizophrenia therapy]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:139-44. [PMID: 34693702 DOI: 10.17116/jnevro2021121091139] [Reference Citation Analysis]
34 Marteene W, Winckel K, Hollingworth S, Kisely S, Gallagher E, Hahn M, Ebdrup BH, Firth J, Siskind D. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf 2019;18:1149-60. [PMID: 31564170 DOI: 10.1080/14740338.2019.1674809] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
35 Keks N, Hope J, Schwartz D, McLennan H, Copolov D, Meadows G. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS Drugs 2020;34:473-507. [PMID: 32246399 DOI: 10.1007/s40263-020-00718-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
36 McEvoy J, Citrome L. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator. Clin Schizophr Relat Psychoses 2016;9:177-86. [PMID: 26757416 DOI: 10.3371/CSRP.MCCI.010316] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
37 Mallo-Abreu A, Reyes-Resina I, Azuaje J, Franco R, García-Rey A, Majellaro M, Miranda-Pastoriza D, García-Mera X, Jespers W, Gutiérrez-de-Terán H, Navarro G, Sotelo E. Potent and Subtype-Selective Dopamine D2 Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach. J Med Chem 2021;64:8710-26. [PMID: 34110150 DOI: 10.1021/acs.jmedchem.1c00704] [Reference Citation Analysis]
38 Garay RP, Citrome L, Samalin L, Liu C, Thomsen MS, Correll CU, Hameg A, Llorca P. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion on Pharmacotherapy 2016;17:921-36. [DOI: 10.1517/14656566.2016.1149164] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
39 Parikh NB, Robinson DM, Clayton AH. Clinical role of brexpiprazole in depression and schizophrenia. Ther Clin Risk Manag 2017;13:299-306. [PMID: 28331332 DOI: 10.2147/TCRM.S94060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
40 Zhao MJ, Qin B, Wang JB, Zhang YP, Zhao JT, Mao YG, Zhang XY, Zhang RL. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol 2018;38:55-9. [PMID: 29257786 DOI: 10.1097/JCP.0000000000000834] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
41 Citrome L, Risinger R, Cutler AJ, Du Y, Zummo J, Nasrallah HA, Silverman BL. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study. CNS Spectr 2018;23:284-90. [PMID: 28625204 DOI: 10.1017/S1092852917000396] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
42 Citrome L. Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next? CNS Spectr 2016;21:1-12. [DOI: 10.1017/s1092852916000729] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
43 El Mansari M, Ebrahimzadeh M, Hamati R, Iro CM, Farkas B, Kiss B, Adham N, Blier P. Long-term administration of cariprazine increases locus coeruleus noradrenergic neurons activity and serotonin1A receptor neurotransmission in the hippocampus. J Psychopharmacol 2020;34:1143-54. [PMID: 32684081 DOI: 10.1177/0269881120936891] [Reference Citation Analysis]
44 Mucci F, Della Vecchia A, Baroni S, Marazziti D. Cariprazine as a therapeutic option for schizophrenia: a drug evaluation. Expert Opin Pharmacother 2021;22:415-26. [PMID: 33126812 DOI: 10.1080/14656566.2020.1845315] [Reference Citation Analysis]
45 Zazu L, Morera-Herreras T, Garcia M, Aguirre C, Lertxundi U. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study. Eur Neuropsychopharmacol 2021;50:107-11. [PMID: 34082277 DOI: 10.1016/j.euroneuro.2021.05.001] [Reference Citation Analysis]
46 Citrome L. Which role for brexpiprazole, a new dopamine D2 partial agonist, in the treatment of schizophrenia? Evid Based Ment Health 2016;19:e6. [PMID: 27048849 DOI: 10.1136/eb-2015-102143] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Saraf G, Pinto JV, Yatham LN. Efficacy and safety of cariprazine in the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 2019;20:2063-72. [DOI: 10.1080/14656566.2019.1660319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
48 Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-olesen M, Jantzen P, Rasmussen S, Saldeen EA, Lauritsen MG, Bilenberg N, Stenstrøm AD, Nyvang L, Madsen S, Werge TM, Lange T, Gluud C, Skoog M, Winkel P, Jepsen JRM, Fagerlund B, Correll CU, Fink-jensen A. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. The Lancet Psychiatry 2017;4:605-18. [DOI: 10.1016/s2215-0366(17)30166-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 2] [Article Influence: 4.8] [Reference Citation Analysis]
49 Ward K, Citrome L. Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatr Dis Treat 2019;15:247-57. [PMID: 30697049 DOI: 10.2147/NDT.S169369] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
50 Citrome L, Volavka J. Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. Harv Rev Psychiatry 2021;29:20-34. [PMID: 33417374 DOI: 10.1097/HRP.0000000000000275] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Campbell RH, Diduch M, Gardner KN, Thomas C. Review of cariprazine in management of psychiatric illness. Ment Health Clin 2017;7:221-9. [PMID: 29955527 DOI: 10.9740/mhc.2017.09.221] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
52 Stefanowicz J, Słowiński T, Wróbel MZ, Ślifirski G, Dawidowski M, Stefanowicz Z, Jastrzębska-Więsek M, Partyka A, Wesołowska A, Turło J. Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile. Med Chem Res 2018;27:1906-28. [PMID: 30100693 DOI: 10.1007/s00044-018-2203-z] [Reference Citation Analysis]